Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darifenacin with Behavioral Therapy for Overactive Bladder
NCT00127270Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of darifenacin in overactive bladder (OAB) (2 arms), sponsored by Novartis. Primary endpoint: Change from baseline in average number of urinations per patient per day at 12 weeks. Started May 2005; status: completed.
02
Drugs
darifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00127270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00127270.